Suppr超能文献

常春藤叶提取物 EA 575 治疗急性呼吸道感染咳嗽:双盲、随机、安慰剂对照试验的荟萃分析。

Ivy leaves extract EA 575 in the treatment of cough during acute respiratory tract infections: meta-analysis of double-blind, randomized, placebo-controlled trials.

机构信息

Psy Consult Scientific Services, Hamburg, Germany.

CRM Biometrics GmbH, Rheinbach, Germany.

出版信息

Sci Rep. 2022 Nov 21;12(1):20041. doi: 10.1038/s41598-022-24393-1.

Abstract

Ivy leaves extracts have been used successfully to treat acute cough, and data from well-controlled trials is accumulating. We present a meta-analysis of two double-blind, randomized, placebo-controlled trials. Patients with acute respiratory tract infection (ARTI) received ivy leaves dry extract EA 575 (n = 228) or placebo (n = 162) for 7 days, followed by a 7-day period without treatment. The main efficacy outcome was the Bronchitis Severity Score (BSS). Individual patient data meta-analyses were performed using mixed models for repeated measures, analysis of covariance and logistic ordinal regression. Significant BSS differences between EA 575 and placebo occurred already after 2 days and increased until treatment end, with BSS reductions of 8.6 ± 0.2 and 6.2 ± 0.2 (marginal means ± SEM; p < 0.001). The score reduction for placebo after 7 days was comparable to that for EA 575 after 4 days. In the EA 575 group, the proportion of cough-free patients was 18.1% at treatment end and 56.2% at end of follow-up, compared to 9.3% and 25.6% for placebo, respectively. Adverse event rates for EA 575 and placebo were comparable. EA 575 reduces effectively the intensity of acute cough associated with ARTIs and leads to a significant acceleration of recovery. No safety signals were observed.

摘要

常春藤叶提取物已成功用于治疗急性咳嗽,且正不断积累来自对照良好的试验的数据。我们报告了两项双盲、随机、安慰剂对照试验的荟萃分析。患有急性呼吸道感染(ARTI)的患者接受常春藤叶干提取物 EA 575(n=228)或安慰剂(n=162)治疗 7 天,随后停药 7 天。主要疗效结局是支气管炎严重程度评分(BSS)。采用重复测量混合模型、协方差分析和逻辑有序回归对个体患者数据进行荟萃分析。EA 575 和安慰剂之间的 BSS 差异在第 2 天即已显著,且持续增加直至治疗结束,BSS 分别降低 8.6±0.2 和 6.2±0.2(边缘均值±SEM;p<0.001)。在第 7 天,安慰剂组的评分降低与第 4 天 EA 575 组相似。在 EA 575 组中,治疗结束时无咳嗽患者的比例为 18.1%,随访结束时为 56.2%,而安慰剂组分别为 9.3%和 25.6%。EA 575 和安慰剂的不良事件发生率相当。EA 575 可有效减轻 ARTI 相关急性咳嗽的强度,并显著加快恢复速度。未观察到安全性信号。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4444/9681772/4d95ba9053a1/41598_2022_24393_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验